Glenmark Prescribed drugs Ltd on Tuesday mentioned it has acquired the authorised generic variations of sure over-the-counter medication from Wockhardt Ltd within the US.
The acquisition by the corporate’s fully-owned subsidiary Glenmark Prescribed drugs Inc, USA consists of the authorised abbreviated new drug purposes (ANDAs) for famotidine tablets, 10 mg and 20 mg used to deal with and stop ulcers within the abdomen and gut, the corporate mentioned in a press release.
The corporate, nonetheless, didn’t disclose the monetary particulars.
Glenmark has additionally acquired ANDAs of anti-allergy medication cetirizine hydrochloride tablets, 5 mg and 10 mg, indigestion, heartburn and acid reflux disorder therapy drug Lansoprazole delayed-release capsules USP, 15 mg and Olopatadine Hydrochloride Ophthalmic Answer USP, 0.1 per cent indicated for allergic conjunctivitis and allergic rhinitis, within the US.
“The over-the-counter market has lengthy been an essential phase of Glenmark’s portfolio around the globe. Our acquisition of those ANDAs represents the continued growth of our enterprise into the OTC market right here in the US and our dedication to making sure sufferers have entry to top quality, inexpensive medicines,” Glenmark Prescribed drugs Inc, USA, President Sanjeev Krishan mentioned.
Glenmark mentioned its present portfolio consists of 175 merchandise authorised for distribution within the US market and 48 ANDAs pending approval with the USFDA.
(Solely the headline and film of this report could have been reworked by the Enterprise Normal workers; the remainder of the content material is auto-generated from a syndicated feed.)